Exploration of Adaptive Antitumoral Immune Cells Through Lymphapheresis in Cancer Patients : ALCYTA

Launched by INSTITUT CURIE · Apr 26, 2022

Keywords

ClinConnect Summary

The ALCYTA clinical trial is exploring how the immune system responds to cancer by looking for specific immune cells that attack tumors. This study is aimed at cancer patients who may be experiencing immune-related responses or side effects from their treatments. Researchers will collect a sample of blood from participants to analyze these immune cells and understand their role in fighting cancer.

To be eligible for the trial, participants must be at least 18 years old and have a confirmed or suspected invasive tumor. They should also be receiving treatments that could affect their immune system. It's important that they have a certain number of immune cells in their blood and are able to provide consent for participation. During the study, participants will undergo a procedure called lymphapheresis, which involves drawing blood to collect immune cells. All participants will be closely monitored throughout the trial to ensure their safety and well-being. If you're interested or think you might qualify, it’s a good idea to discuss this with your doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient aged 18 or over,
• • 2. Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol,
• • 3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters,
• • 4. Suspicion of immune mediated response or toxicities (assessed by the immunologists),
• • 5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement,
• • 6. Total circulating lymphocytes\> 1000 / mm3,
• • 7. Availability of DNA and RNA from the tumor,
• • 8. Information to the patient and signature of informed consent or his legal representative,
• • 9. Affiliated with a social security scheme or such a scheme.
• Exclusion Criteria:
• • 1. Inability to undergo study follow-up for geographical, social or psychological reasons,
• • 2. Infection with HIV or hepatitis B or C viruses,
• • 3. Patients on high dose corticosteroid treatment (\> 1 mg / kg continuously),
• • 4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease),
• • 5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.),
• • 6. Pregnant patient or of childbearing age without effective contraception,
• • 7. Persons deprived of their liberty, under guardianship or legal protection.